We have just released our 2025 Annual Report, summarizing a seminal year for Fluicell. During 2025, we started an important collaboration in our type 1 diabetes program, signed a partnership agreement regarding precision technologies for cancer treatment, and established a solid foundation for continued growth. Fueled by the advances we made in 2025, we are well-positioned to take the next step in Fluicell’s development and to continue our mission to change the way we treat serious disease.